SLAMF5 blockade reduced the expression of HLA-DR, CD80, and CD52 in monocytes derived from the peripheral blood of MS patients, as well as in LPS-activated human iPSC-derived microglia. This evidence concerns the gene CD80 and myeloid sarcoma.